The growing importance of mitochondrial toxicity assessment in drug discovery and development

29 February 2024

In this application note, Agilent Technologies highlights the importance of assessing mitochondrial toxicity as a core criterion in drug safety. The note discusses some of the failures in drug development that led to the withdrawal of drugs related to metabolic/mitochondrial toxicity, and how these failures highlighted the need for more stringent screening for mitochondrial toxicity in drug discovery.